Bristol-Myers Squibb Company
Bristol-Myers Squibb Company (BMY) has a dated report snapshot, but its current priced-in claim is temporarily suppressed because the live engine record is unavailable or has changed.
At about $54 (as of June 27, 2026) the market pays roughly 12 times operating income, a multiple low enough that the price sits below what even a 5% per year decline in operating profit would warrant. The stock is priced for shrinkage. The cash flow says otherwise, at least today. The static value frames bracket the price comfortably. The reason for the discount is the patent cliff. The company depends on a few key products, the Legacy Portfolio is already declining on Revlimid and other gener
Is BMY overvalued? See what's priced in →
2,457 institutional managers reported holding BMY in 13F filings for the quarter ended 2026-03-31. Together they hold about 74% of the company; the top 10 hold 36%. 222 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 39.6M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (3.3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BMY has cut its share count 8.5% over the past five years, spending $16.43B on repurchases. It pays a dividend, and has paid one every year in our records (18 and counting), raised 15 years straight; the current rate is $2.49 a share annually. Cash returned over the past three years: $13.54B in dividends and $4.00B in repurchases.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at BMY over the trailing three years: 2023: 3 buys totaling $673k; 2024: 1 buy totaling $100k; 2025: 3 buys totaling $412k. 14 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
BMY's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-07-28 | -3.1% | -5.5% |
| 2023-10-27 | -9.9% | +0.6% |
| 2024-02-14 | +0.1% | -2.1% |
| 2024-04-26 | -8.2% | -7.4% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
BMY's latest 8-K filings: 2026-05-08 (items 5.07); 2026-04-30 (items 2.02, 7.01, 9.01); 2026-02-05 (items 2.02, 7.01, 9.01); 2026-01-12 (items 7.01, 9.01); 2025-11-18 (items 8.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: July 3, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.